CAMP4 Therapeutics Corporation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CAMP4 Therapeutics Corporation (CAMP) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 39.53 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- CAMP4 Therapeutics Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 37.07M shares, a 1570.18% increase year-over-year.
- CAMP4 Therapeutics Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 2.22M shares, a 84.42% decline year-over-year.
- CAMP4 Therapeutics Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 14.24M shares.
- CAMP4 Therapeutics Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 37.07M shares, a 1635.68% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.14M shares, a 84.74% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 14.00M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 39.53M shares 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | 37.07M shares 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | 37.07M shares 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | 37.80M shares 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | 3.00M shares 10-Q · filed 2026-08-13 | 5.18M shares 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | 2.22M shares 10-Q · filed 2026-05-07 | 5.22M shares 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | 2.14M shares 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | 13.76M shares 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | 14.19M shares 10-Q · filed 2025-08-14 | |||||
| 2024-03-31 | 14.24M shares 10-Q · filed 2025-05-13 | |||||
| 2023-12-31 | 14.00M shares 10-K · filed 2025-03-27 | |||||
| 2023-09-30 | 13.96M shares 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |